KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Shares Issued (2016 - 2025)

Pacira BioSciences has reported Shares Issued over the past 15 years, most recently at $490000.0 for Q4 2025.

  • Quarterly results put Shares Issued at $490000.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $490000.0 (changed N/A YoY), and the annual figure for FY2025 was $502000.0, changed.
  • Shares Issued for Q4 2025 was $490000.0 at Pacira BioSciences, up from $26000.0 in the prior quarter.
  • Over the last five years, Shares Issued for PCRX hit a ceiling of $11.0 million in Q1 2022 and a floor of $26000.0 in Q3 2023.
  • Median Shares Issued over the past 4 years was $2.3 million (2021), compared with a mean of $4.2 million.
  • Biggest five-year swings in Shares Issued: soared 198.84% in 2021 and later plummeted 98.38% in 2023.
  • Pacira BioSciences' Shares Issued stood at $4.8 million in 2021, then crashed by 81.13% to $905000.0 in 2022, then crashed by 97.13% to $26000.0 in 2023, then soared by 1784.62% to $490000.0 in 2025.
  • The last three reported values for Shares Issued were $490000.0 (Q4 2025), $26000.0 (Q3 2023), and $1.6 million (Q2 2023) per Business Quant data.